HCW Biologics (HCWB) investor relations material

Company overview and business model

• Clinical-stage biopharma developing fusion immunotherapeutics for chronic-inflammation-related autoimmune disease, cancer and senescence-associated dysplasia; also commercializing proprietary reagents for ex vivo manufacturing.

• HCW9302, an IL-2 fusion protein intended to expand regulatory T cells, is in Phase 1 for alopecia areata; preliminary data from the first two cohorts showed general tolerability, no dose-limiting toxicities and preliminary activity in cohort two.

• HCW11-018b is a subcutaneous T-cell engager for solid tumors, with a Phase 1 filing targeted for H1 2027; HCW11-040 is planned for a Phase 1 study in senescence-associated dysplasia in H2 2027.

• Akron Biotech received exclusive worldwide distribution rights, excluding China, for HCW11-006 for cell-therapy manufacturing and other ex vivo uses; closing depends on due diligence and testing and is due by Nov. 30, 2026.

Use of proceeds and capital allocation

• Resale proceeds go to Armistice; no proceeds from share resales and only nominal proceeds from pre-funded warrant exercises are expected.

• Cash exercise of September 2026 common warrants could yield up to $1.5M; intended uses include clinical and preclinical programs, R&D, working capital and general corporate purposes.

• The Akron supply arrangement provides for advance payments of $200,000 at closing, $100,000 within 30 days after the Supply Agreement is executed, and $100,000 on each of the first two closing anniversaries.

Risk factors and disclosures

• Existing investors face potential dilution and share-price pressure from resale of up to 1,807,228 shares; issuance of the 903,614 common-warrant shares depends on stockholder approval.

• Nasdaq compliance remains under a Mandatory Panel Monitor through June 17, 2027; renewed bid-price noncompliance during monitoring could trigger a delisting determination without the usual cure period.

• The filing describes creditor forbearance negotiations and a remaining $740,000 Cooley fee balance under repayment discussions; failure to resolve the obligation could harm liquidity and operations.

• Material weaknesses in controls involved long-lived-asset impairment assessment and review of complex warrant accounting; the filing says these weaknesses remained unremediated as of June 30, 2026.

• Risks also include limited operating history, clinical and regulatory uncertainty, volatile and potentially illiquid trading, future financing dilution, and no expected cash dividends in the foreseeable future.